| Start of up-dosing |
Up to peak GPS |
After peak GPS |
Total |
| |
Patients ADR/Total, N (%), E* |
Injections
ADR/Total, N (%) |
Patients
ADR/Total, N (%), E* |
Injections
ADR/Total, N (%) |
Patients
ADR/Total, N (%), E* |
InjectionsADR/Total, N (%) |
| Entiretreatment |
122/198 (61.6), 897 |
764/2396 (31.9) |
25/52 (48.1), 208 |
163/526 (31.0) |
147/250 (58.8), 1105 |
927/2922 (31.7) |
| Up-dosing to 10,000 SQ-U |
105/198 (53.0), 439 |
350/1236 (28.3) |
24/52 (46.2), 124 |
97/324 (29.7) |
129/250 (51.6), 563 |
447/1560 (28.7) |
| Plateau with 10,000 SQ-U |
45/134 (33.6), 123 |
97/342 (28.4) |
4/18 (22.2), 8 |
8/37 (43.2) |
49/152 (32.2), 131 |
105/379 (27.7) |
| Up-dosing to 100,000 SQ-U |
81/164(49.4), 293 |
277/723 (38.3) |
16/37 (43.2), 65 |
55/152 (36.2) |
97/201 (48.3), 349 |
332/875 (37.9) |
| Maintenance with100,000 SQ-U |
28/62 (45.2), 42 |
40/95 (42.1) |
2/8 (25.0), 3 |
3/10 (30.0) |
30/70 (42.9), 45 |
43/105 (40.6) |
*E: Number of events |
